Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study

Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study

We evaluated the immunogenicity of 300 mg Tixagevimab-Cilgavimab in immunocompromised children and adolescents who weighed 20 to >40 kg. Six to 18-year-old participants were divided into two groups by body weight and received 300 mg (20 to <40 kg) and 600 mg (≥40 kg) Tixagevimab-Cilgavimab, re...

Full description

Saved in:
Bibliographic Details
Main Authors: Jassada Buaboonnam, Supattra Rungmaitree, Nuntawan Piyaphanee, Sirirat Charuvanij, Onsiri Pitisuttithum, Katherine Copeland, Chatkamol Pheerapanyawaranun, Laddawan Jansarikit, Suvimol Niyomnaitham, Kulkanya Chokephaibulkit
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Tixagevimab-cilgavimab
pre-exposure prophylaxis
immunocompromised
children
adolescents
Thailand
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2428011
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2428011

Similar Items